Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Treatment Modifications and Treatment-Limiting Toxicities or Side Effects: Risk Factors and Temporal Trends.

Pantazis N, Psichogiou M, Paparizos V, Gargalianos P, Chini M, Protopapas K, Sipsas NV, Panos G, Chrysos G, Sambatakou H, Katsarou O, Touloumi G.

AIDS Res Hum Retroviruses. 2015 Jul;31(7):707-17. doi: 10.1089/AID.2015.0018. Epub 2015 Jun 10.

PMID:
25950848
2.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

PMID:
25567330
3.

Patterns of drug resistance among newly diagnosed HIV-1 infected patients in Greece during the last decade: the crucial role of transmission networks.

Paraskevis D, Zavitsanou A, Magiorkinis E, Gargalianos P, Xylomenos G, Lazanas M, Chini M, Skoutelis A, Papastamopoulos V, Antoniadou A, Papadopoulos A, Psichogiou M, Daikos G, Vassilakis A, Chrysos G, Paparizos V, Kourkounti S, Sambatakou H, Kordossis T, Koratzanis G, Panagopoulos P, Maltezos E, Drimis S, Hatzakis A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19742. doi: 10.7448/IAS.17.4.19742. eCollection 2014.

4.

Evaluation of rapid progressors in HIV infection as an extreme phenotype.

Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K; for CASCADE Collaboration in EuroCoord.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):15-21. doi: 10.1097/QAI.0000000000000240.

5.

Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.

Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter K; CASCADE Collaboration in EuroCoord.

PLoS One. 2013 Nov 14;8(11):e78642. doi: 10.1371/journal.pone.0078642. eCollection 2013.

6.

Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.

Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A, Lodwick R, Torti C, Dorrucci M, Günthard HF, Michalik C, Chrysos G, Castagna A.

J Infect Dis. 2013 Mar 1;207(5):759-67. doi: 10.1093/infdis/jis752. Epub 2012 Dec 7.

7.

Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts.

Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; Beijing PRIMO cohort study; CASCADE Collaboration in EuroCoord.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):441-6. doi: 10.1097/QAI.0b013e31827f5c9a.

PMID:
23221982
8.

Effect of HIV type 1 subtype on virological and immunological response to combination antiretroviral therapy: evidence for a more rapid viral suppression for subtype A than subtype B-infected Greek individuals.

Paraskevis D, Touloumi G, Bakoyannis G, Paparizos V, Lazanas M, Gargalianos P, Chryssos G, Antoniadou A, Psichogiou M, Panos G, Katsarou O, Sambatakou H, Kordossis T, Hatzakis A; AMACS.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):461-9. doi: 10.1089/AID.2012.0143. Epub 2012 Nov 6.

PMID:
23034083
9.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration.

AIDS. 2012 Aug 24;26(13):1691-705.

10.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration.

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28.

11.

Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study.

Zarkotou O, Pournaras S, Voulgari E, Chrysos G, Prekates A, Voutsinas D, Themeli-Digalaki K, Tsakris A.

J Clin Microbiol. 2010 Jun;48(6):2271-4. doi: 10.1128/JCM.02301-09. Epub 2010 Apr 7.

12.

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J; TRIAD Study Group.

J Antimicrob Chemother. 2009 Aug;64(2):398-410. doi: 10.1093/jac/dkp198. Epub 2009 Jun 10.

13.

Intracranial haemorrhage possibly related to Tipranavir in an HIV-1 patient with cryptococcal meningitis.

Chrysos G, Gerakari S, Stasini F, Kokkoris S, Kourousis D, Velegraki A.

J Infect. 2008 Jul;57(1):85-7. doi: 10.1016/j.jinf.2008.01.008. Epub 2008 Mar 7.

PMID:
18314196
14.

Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin.

Paraskevis D, Magiorkinis E, Magiorkinis G, Sypsa V, Paparizos V, Lazanas M, Gargalianos P, Antoniadou A, Panos G, Chrysos G, Sambatakou H, Karafoulidou A, Skoutelis A, Kordossis T, Koratzanis G, Theodoridou M, Daikos GL, Nikolopoulos G, Pybus OG, Hatzakis A; Multicentre Study on HIV Heterogeneity.

J Infect Dis. 2007 Oct 15;196(8):1167-76. Epub 2007 Sep 13.

15.

Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.

Chrysos G, Mikros S, Kokkoris S, Pastelli A, Kontochristopoulos G.

J Drugs Dermatol. 2007 Jul;6(7):742-3.

PMID:
17763601
16.

Neurolisteriosis mimicking herpes simplex encephalitis in an immunocompromized patient.

Protopsaltis J, Kokkoris S, Brestas PS, Chrysos G, Salvanos L, Samara C, Giannoulis G.

Scand J Infect Dis. 2006;38(9):825-8.

PMID:
16938743
17.

Coxsackievirus infection associated with acute pancreatitis.

Chrysos G, Kokkoris S, Protopsaltis J, Korantzopoulos P, Giannoulis G.

JOP. 2004 Sep 10;5(5):384-7.

18.

Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors.

Tsekes G, Chrysos G, Douskas G, Paraskeva D, Mangafas N, Giannakopoulos D, Papanikolaou M, Georgiou E, Lazanas MC.

HIV Med. 2002 Apr;3(2):85-90.

PMID:
12010354
19.

Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals.

Touloumi G, Paparizos V, Sambatakou H, Katsarou O, Chrysos G, Kordossis T, Antoniadou A, Hatzitheodorou H, Stavrianeas N, Gargalianos P, Karafoulidou A, Lazanas M, Giamarelou H, Hatzakis A.

HIV Clin Trials. 2001 Jan-Feb;2(1):6-16.

PMID:
11590509
20.

Molecular characterization of a complex, recombinant human immunodeficiency virus type 1 (HIV-1) isolate (A/G/J/K/?): evidence to support the existence of a novel HIV-1 subtype.

Paraskevis D, Magiorkinis E, Magiorkinis G, Anastassopoulou C, Lazanas M, Chrysos G, Vandamme AM, Hatzakis A.

J Gen Virol. 2001 Oct;82(Pt 10):2509-14.

PMID:
11562543
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk